Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Oncology Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBOT alertsBen Young has spoken on 1 investor event across 1 company, most recently for BridgeBio Oncology Therapeutics, Inc. on September 10, 2026. BridgeBio Oncology Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Oncology Therapeutics, Inc. includes Eli Wallace (CEO and Board Member), Pedro Beltran, Ph.D. (CEO and Board Member), Pedro J. Beltran, Ph.D. (CEO and Board Member) and 7 others.
“You know, we have done some subgroup analysis to understand that better. So whether it's refracted to prior GTO-C versus progress on intolerable, there's no difference in terms of response to this particular combination.”
Transcript header (unverified)
Biotechnology · Healthcare
